MOMM Diagnostics is dedicated to bridging the gap in prenatal care by delivering reliable and accessible solutions. Through meticulous research and development, we strive to bring forth a game-changing technology that will revolutionize the way preeclampsia is detected and managed. We are driven by a shared purpose to improve maternal and fetal health outcomes, bringing peace of mind to families worldwide.
Empowering healthcare professionals with accurate and timely diagnostic tools to improve the health and well-being of mothers and babies worldwide.
Our mission is to address the critical need for a timely, accurate, and affordable diagnostic tool for the early detection of preelampsia, a life-threatening condition affecting pregnant women and their unborn babies
Our vision is to create a future where life-threatening pregnancy conditions are effectively and proactively managed, reducing maternal and neonatal mortality rates. Through continuous innovation and collaboration, we aspire to establish our technology as the gold standard for near-patient testing, enabling early detection, personalized care, and positive outcomes for every expectant mother.
Founded in 2018, our startup emerged from a partnership between Avails Medical, Inc. and the Swiss research institute Empa. Since our inception, we have worked tirelessly to develop our groundbreaking eFlow technology and préXclude our pioneering rapid preeclampsia test. Our long history of collaborating with industry experts and renowned research institutions such as FHNW School of Life Sciences and CSEM provide a unique ecosystem to make innovation happen.